A protein called PDIA3 is overactive in pulmonary fibrosis (PF), and contributes to the disease by driving the production of signaling molecules that promote tissue scarring, a new study shows. The researchers found that blocking PDIA3 activity can lessen such fibrosis, or tissue scarring, in a mouse model of…
TXR-1002 and TXR-1007, two new therapeutic candidates for idiopathic pulmonary fibrosis (IPF) from Aria Pharmaceuticals, demonstrated significant efficacy at reducing tissue scarring and good tolerability in a mouse model of the disease. Moreover, Aria said, the new artificial intelligence approach its researchers used in the lab to identify and…
When doctors discuss the costs and benefits of getting a lung transplant, they often talk about the lifelong use of immunosuppressants. These medications can have a wide range of side effects. For example, most people experience at least a few of the many side effects of prednisone, a…
The U.S. Food and Drug Administration (FDA) has authorized Blade Therapeutics to begin a Phase 1 clinical trial evaluating pharmacological interactions between its investigational medication, cudetaxestat (BLD-0409), and two approved treatments for idiopathic pulmonary fibrosis (IPF). The trial will enroll an estimated 86 healthy individuals, who…
The National Alliance for Caregiving, in partnership with Global Genes, has issued a free guidebook, available online, that offers resources and support for caregivers of children with rare diseases. “The Circle of Care Guidebook for Caregivers of Children With Rare and/or Serious Illnesses” was designed…
As we head into the last week of August, summer has been flying by, kids are heading back to school, and fall will soon be upon us. I love the cooler weather that fall brings, as I’ve found it’s been harder to breathe in the heat and humidity of…
As I write this, my parents, Diana and Jack, are likely hearing muffled morning sounds from the guest room down the hall. Hard whispers from 4-year-old Jack, tired groans from 2-year-old Maeve, and gurgles or squeaks cutting through the golden light from Gavin the newborn. I know my parents are…
MyMD Pharmaceuticals has secured a 13th U.S. patent protecting its experimental therapy MYMD-1, which is being investigated as a potential treatment for idiopathic pulmonary fibrosis (IPF) and other diseases. The new patent (11,096,933), “Method of Treating Disorders Associated with Chronic Inflammation,” covers the administration of MYMD-1 to…
I am an advocate for my rare disease, but I still can’t describe it. Several weeks ago, I went to the dentist with my husband. It was a hot and humid day, as it always is here in Texas. I was carrying “Cooper,” the name I gave to my…
Treatment with vitamin D’s active form lessened lung scarring, and significantly reduced the levels of fibrotic markers in a mouse model of idiopathic pulmonary fibrosis (IPF), a study reported. Notably, these benefits were associated with vitamin D’s suppression of the renin-angiotensin system (RAS), whose chronic activation promotes the production of…
Get regular updates to your inbox.
